GSK/Novartis transaction

On 28 January 2015, we announced that our major three-part transaction with Novartis has completed.

As a result, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and divested our marketed Oncology business to Novartis.

Completion of this transaction represents a major step forward in the Group’s strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines.

Sir Andrew Witty, CEO, GSK

Previously published documents regarding the transaction are below: